Related references
Note: Only part of the references are listed.Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
Tetsuo Takehara et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens
Norio Akuta et al.
JOURNAL OF MEDICAL VIROLOGY (2019)
Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study
Eiichi Ogawa et al.
HEPATOLOGY RESEARCH (2019)
Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience
Yoshihide Ueda et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections
Hitomi Sezaki et al.
JOURNAL OF GASTROENTEROLOGY (2019)
ns5a resistance profile of genotype 1b virological failures that impacts outcome of re-treatment by glecaprevir/pibrentasvir: Nation-wide real world study
Masayuki Kurosaki et al.
JOURNAL OF HEPATOLOGY (2019)
NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir
Hayato Uemura et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures
Mitsutaka Osawa et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection
Hidenori Toyoda et al.
HEPATOLOGY (2018)
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
Kazuaki Chayama et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
Hiromitsu Kumada et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
Nancy Reau et al.
HEPATOLOGY (2018)
The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study
Darrick K. Li et al.
HEPATOLOGY (2018)
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
Namiki Izumi et al.
HEPATOLOGY INTERNATIONAL (2018)
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
S. Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis
F. Mettke et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
Hiromitsu Kumada et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Sustained Virologic Response by Direct Antiviral Agents Reduces the Incidence of Hepatocellular Carcinoma in Patients With HCV Infection
Masahiro Kobayashi et al.
JOURNAL OF MEDICAL VIROLOGY (2017)
Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan
Norio Akuta et al.
JOURNAL OF MEDICAL VIROLOGY (2017)
Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience
Yoshihide Ueda et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C
Hiroko Nagata et al.
JOURNAL OF HEPATOLOGY (2017)
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
Edward Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Telaprevir versus simeprevir for the treatment of recurrent hepatitis C after living donor liver transplantation
Toru Ikegami et al.
HEPATOLOGY RESEARCH (2016)
Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience
Yoshihide Ueda et al.
HEPATOLOGY RESEARCH (2016)
JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2
Yasuhiro Asahina et al.
HEPATOLOGY RESEARCH (2016)
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C
Goki Suda et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis
Hidenori Toyoda et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2016)
Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir
Jeffrey M. Collins et al.
CLINICAL INFECTIOUS DISEASES (2015)
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton et al.
GASTROENTEROLOGY (2015)
Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection
Anu Osinusi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
Jean-Michel Molina et al.
LANCET (2015)
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
David Roth et al.
LANCET (2015)
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
Juergen K. Rockstroh et al.
LANCET HIV (2015)
Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy
Naoki Hiramatsu et al.
HEPATOLOGY RESEARCH (2015)
JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1
Yasuhiro Asahina et al.
HEPATOLOGY RESEARCH (2014)
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Mark S. Sulkowski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience
Audrey Coilly et al.
JOURNAL OF HEPATOLOGY (2014)
Management of acute and chronic HCV infection in persons with HIV coinfection
Mark S. Sulkowski
JOURNAL OF HEPATOLOGY (2014)
Hepatitis C Virus Infection Increases Risk of Developing End-Stage Renal Disease Using Competing Risk Analysis
Jia-Jung Lee et al.
PLOS ONE (2014)
Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey
Nobuhisa Akamatsu et al.
TRANSPLANT INTERNATIONAL (2014)
Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation
Toru Ikegami et al.
HEPATOLOGY RESEARCH (2013)
Guidelines for the Management of Hepatitis C Virus Infection
Yasuhiro Asahina et al.
HEPATOLOGY RESEARCH (2013)
Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment
Marina Berenguer et al.
JOURNAL OF HEPATOLOGY (2013)
Changing Donor Characteristics in Liver Transplantation Over the Last 10 Years in Canada
Nathalie Sela et al.
LIVER TRANSPLANTATION (2013)
Why does living donor liver transplantation flourish in Asia?
Chao-Long Chen et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Who Fares Worse After Liver Transplantation? Impact of Donor and Recipient Variables on Outcome: Data from a Prospective Study
Martina Gambato et al.
TRANSPLANTATION (2013)
Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program in Taipei, Taiwan
Yung-Feng Yen et al.
BMC PUBLIC HEALTH (2012)
Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon
Josh Levitsky et al.
GASTROENTEROLOGY (2012)
Effect of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus
Varun Garg et al.
HEPATOLOGY (2011)
HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
G. Nkontchou et al.
JOURNAL OF VIRAL HEPATITIS (2011)
Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis
A. Probst et al.
JOURNAL OF VIRAL HEPATITIS (2011)
Variants in IL28B in Liver Recipients and Donors Correlate With Response to Peg-Interferon and Ribavirin Therapy for Recurrent Hepatitis C
Takasuke Fukuhara et al.
GASTROENTEROLOGY (2010)
Standardized Prevalence Ratios for Chronic Hepatitis C Virus Infection Among Adult Japanese Hemodialysis Patients
Masaki Ohsawa et al.
JOURNAL OF EPIDEMIOLOGY (2010)
Chronic hepatitis C in patients co-infected with human immunodeficiency virus in Japan: a retrospective multicenter analysis
Hiroshi Yotsuyanagi et al.
HEPATOLOGY RESEARCH (2009)
Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis
Hla-Hla Thein et al.
AIDS (2008)
Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin
Marina Berenguer
JOURNAL OF HEPATOLOGY (2008)
Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy
V. de Ledinghen et al.
JOURNAL OF VIRAL HEPATITIS (2008)
Hepatitis C among predialysis patients: Prevalence and characteristics in a large cohort of patients
Lara B. Lemos et al.
NEPHRON CLINICAL PRACTICE (2008)
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: A meta-analysis of individual patient data
Gioacchino Leandro et al.
GASTROENTEROLOGY (2006)
Interferon therapy in hemodialysis patients with chronic hepatitis C: Study of tolerance, efficacy and post-transplantation course
IM Mahmoud et al.
NEPHRON CLINICAL PRACTICE (2005)
One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
RJ Firpi et al.
LIVER TRANSPLANTATION (2004)
Host and donor risk factors before and after liver transplantation that impact HCV recurrence
M Berenguer
LIVER TRANSPLANTATION (2003)
Hepatitis C virus kinetics during and immediately after liver transplantation
M Garcia-Retortillo et al.
HEPATOLOGY (2002)
Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation
M Berenguer et al.
HEPATOLOGY (2000)
Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy
Y Shiratori et al.
DIGESTIVE DISEASES AND SCIENCES (2000)
Share Paper
